Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C71539
http://purl.obolibrary.org/obo/NCIT_C71539
|
|---|---|
| Preferred Name | Ofranergene Obadenovec |
| Definitions |
A non-replicating adenovirus 5 (Ad-5, El-deleted) encoding a human Fas-chimera (Fas-c) transgene under the control of a modified murine pre-proendothelin-1 (PPE-1) promoter, with potential anti-angiogenic activity. Upon the administration of ofranergene obadenovec, the modified murine PPE-1 promoter is specifically activated in PPE-1-expressing angiogenic endothelial cells residing in the tumor microvasculature. Subsequently, the Fas-c pro-apoptotic transgene, containing the human tumor necrosis factor (TNF) receptor 1 (TNFR-1/p55) and the signaling domain of Fas, is expressed in angiogenic endothelial cells. Fas-mediated apoptosis is activated via binding of the TNFR-1 receptor with TNF-alpha, which is more abundant in the tumor microenvironment (TME), enhancing specificity and limiting systemic toxicities.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A non-replicating adenovirus 5 (Ad-5, El-deleted) encoding a human Fas-chimera (Fas-c) transgene under the control of a modified murine pre-proendothelin-1 (PPE-1) promoter, with potential anti-angiogenic activity. Upon the administration of ofranergene obadenovec, the modified murine PPE-1 promoter is specifically activated in PPE-1-expressing angiogenic endothelial cells residing in the tumor microvasculature. Subsequently, the Fas-c pro-apoptotic transgene, containing the human tumor necrosis factor (TNF) receptor 1 (TNFR-1/p55) and the signaling domain of Fas, is expressed in angiogenic endothelial cells. Fas-mediated apoptosis is activated via binding of the TNFR-1 receptor with TNF-alpha, which is more abundant in the tumor microenvironment (TME), enhancing specificity and limiting systemic toxicities. |
|---|---|
| prefLabel | Ofranergene Obadenovec
|
| label | Ofranergene Obadenovec
|
| NCI_META_CUI | CL378317
|
| PDQ_Closed_Trial_Search_ID | 580988
|
| code | C71539
|
| prefixIRI | NCIT:C71539
|
| in_subset |
See more
See less
|
| Display_Name | Ofranergene Obadenovec
|
| Preferred_Name | Ofranergene Obadenovec
|
| FDA_UNII_Code | 5Q5PRH05GI
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To |
Angiogenesis Inhibitor GT-111
Ofranergene Obadenovec
|
| CAS_Registry | 1476737-24-2
|
| NCI_Drug_Dictionary_ID | 580988
|
| Legacy Concept Name | GT-111
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 580988
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |